Precision BioSciences, Inc. (DTIL) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-257.3%

-$10.94

vs $6.95 price

Levered DCF

-$23.28

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-4.84

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.17×	3.63×	-0.69×	-0.94×	-14.23×	-3.98×	-7×	-18.57×
P/B	0.58×	0.46×	2.23×	1.73×	4.76×	9.77×	4.22×	21.4×
P/S	1.56×	0.38×	0.86×	4.17×	3.76×	17.87×	26.23×	78.57×
EV / EBITDA	0.68×	-2.2×	1.35×	0.96×	-14.79×	-3.58×	-4.61×	-17.21×
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating margin	-152.2%	-38.1%	-89.8%	-248.3%	-34.1%	-452.2%	-392.1%	-440.2%
Net margin	-133.4%	10.4%	-125.8%	-444.8%	-26.5%	-448.9%	-417.6%	-423.0%
Current ratio	13.32×	6.34×	2.73×	3.34×	4.5×	2.46×	7.19×	8.22×
Debt / equity	0.31×	0.53×	1.66×	0.41×	0.1×	0.24×	0×	0×
Interest coverage	-36.67×	-14.68×	-19.61×	-56.08×	-298.3×	0×	-479.14×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-49.6%	12.7%	-325.1%	-184.7%	-33.6%	-245.4%	-67.1%	-115.2%
Return on invested capital	-35.5%	-21.3%	-32.8%	-34.6%	-22.2%	-100.5%	-41.9%	-38.5%
Return on assets	-29.6%	5.3%	-38.4%	-46.9%	-14.5%	-72.6%	-39.5%	-33.2%
Free cash flow yield	-123.6%	-225.5%	-205.4%	-46.9%	-3.8%	-21.3%	-16.9%	-7.9%
Earnings yield	-85.7%	27.5%	-145.8%	-106.7%	-7.0%	-25.1%	-15.9%	-5.4%
Enterprise value	-$28.7M	-$29.8M	-$43.3M	-$60M	$299.7M	$354.7M	$402.5M	$751.9M
Net debt / EBITDA	1.93×	-4.13×	2.67×	2.62×	6.64×	0.8×	2.07×	2.36×
Cash conversion cycle (days)	0	9	96	10	2	150	16	18